Caplyta Showed Greatest Improvement Across Key Efficacy Outcomes Among Adjunctive MDD Treatments in New Network Meta-Analysis
May 05, 2026
May 05, 2026
RARITAN, New Jersey, May 5 -- Johnson and Johnson Innovative Medicine issued the following news release on May 4, 2026:
* * *
CAPLYTA(R) (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
CAPLYTA(R) ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials
* * *
CAPLYTA(R) (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
CAPLYTA(R) ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials